Design Therapeutics DSGN
Design Therapeutics FY 2021: net loss $35.5M; diluted EPS −$0.77
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-22-003369
- Document
- 10-K
- Exhibit 4.3
- Warrants or notes
- Exhibit 10.3
- Material contract
Key figures from this report
These are the numbers Design Therapeutics reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$35.5MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$0.77No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$298.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$29.4MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Alector ALEC public float $115M, Jun 30, 2025
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Fate Therapeutics FATE public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025